Lineage achieves first OpRegen milestone under Roche deal; $5M payment triggered

Lineage Cell Therapeutics, Inc.

First development milestone under Roche Agreement for OpRegen (RG6501) achieved; $5M payment triggered.
Payment expected within 30 days; net proceeds after ~24.1% to Israel Innovation Authority and ~21.5% to Hadasit.
OpRegen is being evaluated in Phase 2a GAlette trial for geographic atrophy secondary to AMD.
Milestone based on manufacturing and clinical advancements in the OpRegen cell therapy program.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.